服用依非韦伦、洛匹那韦/利托那韦或阿扎那韦/利托那韦的患者中阿托伐醌/普罗喹酮浓度降低。
Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.
机构信息
Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
出版信息
AIDS. 2010 May 15;24(8):1223-6. doi: 10.1097/QAD.0b013e3283389129.
HIV-infected travellers frequently use atovaquone/proguanil as malaria prophylaxis. We compared atovaquone/proguanil pharmacokinetics between healthy volunteers and HIV-infected patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. The geometric mean ratio (95% confidence interval) area under the curve (AUC)0-->t for atovaquone relative to the healthy volunteers was 0.25 (0.16-0.38), 0.26 (0.17-0.41) and 0.54 (0.35-0.83) for patients on efavirenz, lopinavir/ritonavir and atazanavir/ritonavir, respectively. Proguanil plasma concentrations were also significantly lower (38-43%). Physicians should be alert for atovaquone/proguanil prophylaxis failures in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.
HIV 感染者常使用阿托伐醌/磺胺多辛作为疟疾预防药物。我们比较了健康志愿者与服用依非韦伦、洛匹那韦/利托那韦或阿扎那韦/利托那韦的 HIV 感染者之间阿托伐醌/磺胺多辛的药代动力学。阿托伐醌 AUC0–t 相对于健康志愿者的几何平均比（95%置信区间）分别为 0.25（0.16-0.38）、0.26（0.17-0.41）和 0.54（0.35-0.83），而依非韦伦、洛匹那韦/利托那韦和阿扎那韦/利托那韦组的磺胺多辛血浆浓度也显著降低（38%-43%）。医生应警惕服用依非韦伦、洛匹那韦/利托那韦或阿扎那韦/利托那韦的患者出现阿托伐醌/磺胺多辛预防失败。
Zotero 插件